<DOC>
	<DOCNO>NCT00034619</DOCNO>
	<brief_summary>The purpose study assess antitumor activity ALIMTA plus Oxaliplatin combination therapy patient previously untreated advanced colorectal cancer</brief_summary>
	<brief_title>A Phase 2 Trial ALIMTA ( LY231514 , Pemetrexed ) Plus Oxaliplatin Administered Every 21 Days First-Line Treatment Patients With Advanced Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis primary cancer colon rectum Must measurable disease Must able comply study procedure Prior chemotherapy advance disease Pregnancy lactation Candidates surgical resection one metastatic focus Second primary cancer Inability take folic acid vitamin B12</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>